1.中国中医科学院西苑医院,北京市海淀区西苑操场1号,100091
2.中国人民大学
3.北京中医药大学东直门医院
4.北京大学肿瘤医院
杨宇飞,E-mail:yyf93@sina.vip.com
收稿:2025-09-17,
修回:2026-01-10,
纸质出版:2026-03-17
移动端阅览
李芮,徐钰莹,吴贝贝等.健脾补肾解毒法治疗晚期结直肠癌的真实世界疗效评价——一项多中心回顾性队列研究[J].中医杂志,2026,67(06):639-647.
LI Rui,XU Yuying,WU Beibei,et al.Real-World Effects Evaluation of the Strengthening Spleen,Tonifying the Kidney,and Detoxifying Method in the Treatment of Advanced Colorectal Cancer:A Multi-Center,Retrospective Cohort Study[J].Journal of Traditional Chinese Medicine,2026,67(06):639-647.
李芮,徐钰莹,吴贝贝等.健脾补肾解毒法治疗晚期结直肠癌的真实世界疗效评价——一项多中心回顾性队列研究[J].中医杂志,2026,67(06):639-647. DOI: 10.13288/j.11-2166/r.2026.06.009.
LI Rui,XU Yuying,WU Beibei,et al.Real-World Effects Evaluation of the Strengthening Spleen,Tonifying the Kidney,and Detoxifying Method in the Treatment of Advanced Colorectal Cancer:A Multi-Center,Retrospective Cohort Study[J].Journal of Traditional Chinese Medicine,2026,67(06):639-647. DOI: 10.13288/j.11-2166/r.2026.06.009.
目的
2
评价健脾补肾解毒法治疗晚期结直肠癌的真实世界疗效。
方法
2
采用多中心回顾性队列研究设计,从美国国立癌症研究所SEER数据库收集接受西医治疗的晚期结直肠癌患者人群设为西医治疗组,从国内3家医院纳入接受西医常规治疗同时接受口服健脾补肾解毒中药≥3个月的晚期结直肠癌患者设为健脾补肾解毒联合组。采用广义增强回归(GBM)的倾向评分逆概率加权(IPW)消除混杂偏倚。主要结局指标为中位生存期(mOS),次要结局指标为第1、2、3年累积生存率。对mOS采用生存分析Kaplan-Meier法绘制生存曲线,比较两组mOS及第1、2、3年累积生存率,比较IPW前后两组患者的生存差异,并根据中药干预特征进行亚组分析[包括中药介入时机及中药口服时间]。
结果
2
西医治疗组共纳入2435例,健脾补肾解毒联合组共纳入360例。经过IPW处理后,西医治疗组2689例,健脾补肾解毒联合组1869例。西医治疗组mOS为15.3个月,健脾补肾解毒联合组mOS为26.1个月,健脾补肾解毒联合组mOS长于西医治疗组(
P
<0.01)。健脾补肾解毒联合组第1、2、3年累积生存率高于西医治疗组(
P
<0.01)。中药早期干预组mOS为29.5个月,中药非早期干预组mOS为24.6个月。中药早期干预组与中药非早期干预组mOS均长于西药治疗组(
P
<0.01),中药早期干预组mOS长于中药非早期干预组(
P
<0.05)。中药口服时间3~6个月的mOS为14.7个月,中药口服时间6
+
~12个月的mOS为21.6个月,中药口服时间>12个月的mOS为33.2个月。西医治疗组mOS均低于中药口服时间6
+
~12个月及中药口服时间>12个月者(
P
<0.01);中药口服时间3~6个月者mOS均低于中药口服时间6
+
~12个月及中药口服时间>12个月者(
P
<0.05);中药口服时间6
+
~12个月mOS低于中药口服时间>12个月者(
P
<0.05)。
结论
2
健脾补肾解毒法辅助西医治疗可延长患者生存期,中药介入时机越早、持续使用时间越长效果可能更好。
Objective
2
To evaluate the real-world effectiveness of the strengthening the spleen, tonifying the kidney, and detoxifying method in the treatment of advanced colorectal cancer.
Methods
2
A multi-center retrospective cohort study was designed. Patients with advanced colorectal cancer receiving western medical treatment were identified from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute and assigned to the western medicine group. Patients with advanced colorectal cancer who received standard western medical treatment combined with oral Chinese herbal medicine based on the strengthening the spleen, tonifying the kidney, and detoxifying method for ≥3 months were enrolled from three hospitals in China and assigned to the combined therapy group. Generalized boosted regression modeling (GBM) -based inverse probability weighting (IPW) using propensity scores was applied to eliminate confounding biases. The primary outcome was median overall survival (mOS). The secondary outcomes included cumulative survival rates at 1, 2, and 3 years. Kaplan-Meier survival method was employed to generate survival curves, and differences in mOS and cumulative survival rates between the two groups were compared before and after IPW adjustment. Subgroup analyses were performed based on characteristics of Chinese herbal medicine intervention, including timing of intervention and duration of oral administration.
Results
2
A total of 2
435 patients were included in the western medicine group, and 360 patients in the combined therapy group. After IPW adjustment, 2
689 patients were included in the western medicine group, and 1
869 patients were included in the combined treatment group. The mOS was 15.3 months in the western medicine group and 26.1 months in the combined treatment group, with significantly longer mOS observed in the combined therapy group (
P
< 0.01). The cumulative survival rates of the combined therapy group at 1, 2, 3 years were higher than that of the western medicine group. In sub
group analyses, the mOS was 29.5 months in the early Chinese herbal intervention group and 24.6 months in the non-early intervention group. Both groups showed longer mOS compared with the western medicine group (
P
<0.01), and the early intervention group demonstrated a significantly longer mOS than the non-early intervention group (
P
<0.05). According to the duration of Chinese herbal medicine use, the mOS was 14.7 months for 3~6 months, 21.6 months for 6
+
~12 months, and 33.2 months for >12 months. The mOS in the western medicine group was significantly lower than that in patients receiving herbal medicine for 6
+
~12 months and >12 months (
P
<0.01). The mOS for 3~6 months was lower than that for 6
+
~12 months and >12 months (
P
<0.05), and the mOS for 6
+
~
12 months was lower than that for >12 months (
P
<0.05).
Conclusion
2
The strengthening the spleen, tonifying the kidney, and detoxifying method as an adjunct to western medical treatment can prolong survival in patients with advanced colorectal cancer. Earlier initiation and longer duration of Chinese herbal medicine use may be associated with better therapeutic outcomes.
ENG C , YOSHINO T , RUÍZ-GARCÍA E , et al . Colorectal cancer [J]. Lancet , 2024 , 404 ( 10449 ): 294 - 310 .
王磊 , 顾知恩 , 翟嘉威 , 等 . 《转移性结直肠癌中医诊疗指南》解读及典型病例分享 [J]. 世界中医药 , 2023 , 18 ( 11 ): 1509 - 1515 .
杨永忠 , 尹菊兰 . 中晚期大肠癌术后的中西医治疗方法 [J]. 中国医学创新 , 2015 , 12 ( 33 ): 127 - 129 .
徐钰莹 , 孙凌云 , 张长 , 等 . 晚期结直肠癌中医受益人群特征分析 [J]. 中国中西医结合杂志 , 2019 , 39 ( 7 ): 804 - 809 .
江海军 , 何斌 , 张彤 , 等 . 杨宇飞治疗晚期结直肠癌验案3则 [J]. 中医药导报 , 2020 , 26 ( 9 ): 187 - 189 .
徐钰莹 , 张文丽 , 杨宇飞 , 等 . 晚期结直肠癌中医药干预治疗疗效预测模型的建立与应用 [J]. 世界科学技术-中医药现代化 , 2019 , 21 ( 7 ): 1518 - 1524 .
郭申阳 , 马克·W.弗雷泽 . 倾向值分析 [M]. 重庆 : 重庆大学出版社: 2012 : 101 - 155 .
牛凯 , 贺志强 . 人工智能与智慧医疗 [M]. 北京 : 化学工业出版社: 2024 : 302 .
National Cancer Institute . Surveillance, epidemiology, and end results(SEER) program [EB/OL]. ( 2023-10-15 )[ 2025-01-16 ]. https://seer.cancer.gov/data-software/documentation/seerstat/nov2024/ https://seer.cancer.gov/data-software/documentation/seerstat/nov2024/ .
AMIN MB , EDGE SB , GREENE FL , et al . AJCC cancer staging manual [M]. 8th ed . New York : Springer , 2017 : 389 - 412 .
国家卫生健康委员会医政司 , 中华医学会肿瘤学分会 . 国家卫健委中国结直肠癌诊疗规范(2023版) [J]. 中国实用外科杂志 , 2023 , 43 ( 6 ): 602 - 630 .
全国中医标准化技术委员会 . 中医临床诊疗术语 第2部分:证候 [S]. 北京 : 中国标准出版社 , 2021 : 6-11,159-238 .
国家药品监督管理局 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 35 - 42 .
陈悦 . 晚期结直肠癌预后影响因素分析及中医动态干预治疗策略研究 [D]. 北京 : 北京中医药大学 , 2022 .
陈炳为 . 医学统计学 [M]. 南京 : 东南大学出版社: 2023 : 268 .
江海军 . 杨宇飞教授健脾补肾解毒法在晚期结直肠癌中的临床应用研究 [D]. 北京 : 北京中医药大学 , 2020 .
张彤 , 唐末 , 陈悦 , 等 . 中医分阶段论治理念联合化疗治疗转移性结直肠癌队列研究 [J]. 中国中西医结合杂志 , 2025 , 45 ( 1 ): 18 - 24 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号